Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen

Journal of Medical Virology

Volumn 65, Issue 3, 2001, Pages 445-448

  Delaugerre, C ^a   Rohban, R ^a   Simon, A ^a   Mouroux, M ^a   Tricot, C ^a   Agher, R ^a   Huraux, J M ^a   Katlama, C ^a   Calvez, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cross resistance; Early failure; Efavirenz; Nevirapine; Non nucleoside reverse transcriptase inhibitor; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CROSS RESISTANCE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; TREATMENT FAILURE; VIRUS INFECTION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE;

EID: 0034786988     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2055     Document Type: Article

References (17)

1. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy
2. Efavirenz responses in NNRTI experienced patients: Results from the SUSTIVA® expanded access program
3. Non-nucleoside resistance in clinical practice: Can early failure with nevirapine be rescue with efavirenz?
4. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
5. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
6. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
7. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients
8. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
9. The Atlantic study: A randomized open-label study comparing two protease inhibitor-sparing antiretroviral strategies versus a standart PI-containing regimen
10. 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transciptase inhibitors
11. The presence or absence of zidovudine in a nevirapine-containing antiviral regimen determines which of two nevirapine-mutations occurs on virologic failure
12. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride
13. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance
14. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during theraphy
15. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
16. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
17. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase